Half-Life Time and Control Frequency of Vitamin K-Dependent Coagulation Factors

Dam-Mieras, M.C.E. van; Hemker, H.C.

doi:10.1159/000214728

Cited by 8 publications

(4 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The influence of iso lated coagulation factor deficiencies was first investigated. Factor II has a central role in coagulation; a satisfactory concentration of factor II is a prerequisite for factors VII, IX and X to influence PT [12], This was supported in the present study by the maximally prolonged clotting time of PT at absence of factor II. PT responded less than expected against low val ues of factor 11, which may improve the flexibil ity ofPT.…”

Section: Discussionsupporting

confidence: 83%

“…The vitamin K-dependent factors may be more alike at extreme antico agulation [4], but cases beyond therapeutic levels (TT < 0.05 equal to INR > 4.3) [3] were not included in the present study. The decrease of the vitamin K-dependent coagula tion factors at start of warfarin therapy fol lows the following rank order V II< IX < X < II depending on their half lives [12,15]; the reappearance at stop of therapy follows the opposite rank order [16], The fact that fac tor VII changes more rapidly than factors II, IX and X [ 16] may explain the high sensitivity of PT towards change of warfarin dosage.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Which Coagulation Factors Interfere with the One-Stage Prothrombin Time?

Talstad

1993

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Coagulation factors that interfere with the one-stage prothrombin time (PT) were investigated. PT responded with identical activities (adequately) against coagulation factors VII or X, only half as expected against factor IX, less than expected and nonlinearly against factor II. In multiple coagulation factor deficiencies PT did not differ from factor VII, which was the most reduced coagulation factor in warfarin therapy or liver disease. PT may also be influenced by factor VII at high activities.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 98%

Which Coagulation Factors Interfere with the One-Stage Prothrombin Time?

Talstad

1993

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

show abstract

“…The fact that group 2 patients did not exhibit the same correlation might be due to diminished catabolism of triglyceride-rich lipoproteins, different half-lives for the degradation of tri glyceride and of FVII, leading to alterations in these correlations [19,20].…”

Section: Discussionmentioning

confidence: 99%

Coagulation Factor VII and Plasma Triglycerides

Sousa

Bruckert²,

Giral³

et al. 1989

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

High circulating levels of coagulation factor VII (FVII) are known to be associated with elevated concentrations of blood lipids. More specifically, hypertriglyceridemia is correlated with raised FVII coagulant activity (FVIIc). Recently, evidence has been described which suggests that elevation in FVIIc might reflect an increase in the total concentration of FVII, as evaluated by quantitation of FVII antigen (FVIIag). It is also known that FVIIc represents a risk factor for cardiovascular death, but the prediction of cardiovascular risk based on triglyceride estimation is the subject of conflicting results. Since dyslipidemia featuring abnormal triglyceride metabolism is pathophysiologically heterogeneous, we analyzed the possible relationships between FVII and triglyceride further and under standardized postprandial conditions. For this purpose we studied FVIIc and FVIIag in relation to triglyceridemia after a standardized test meal. Our results confirm that FVIIc and FVIIag levels are strongly correlated with each other (r = 0.714; p = 0.01). In addition, both were significantly increased (p < 0.02) in patients who exhibited abnormal triglyceride levels 8 h after a standardized test meal, as compared to those who displayed normal triglyceridemia. Furthermore, we found that apolipoprotein B levels were also increased in such patients. The deficient postprandial catabolism of triglycerides, therefore, appears to be related to an increase in total FVII concentration, suggesting that some association between the metabolism of triglyceride-rich lipoproteins and FVII might underlie the mechanism of the elevation in FVII. Given the important contribution of FVII to hypercoagulability, then our results may be relevant to the understanding of the role of postprandial triglyceride in atherogenesis and in consideration of the circadian prevalence of cardiovascular thrombosis.

show abstract

“…The rationale for replacement of FVII in warfarin-treated subjects would be that FVII has the shortest half-life of the vitamin K-dependent factors. 9, 10 Talstad 11 found that FVII was the most quickly reduced clotting factor during incipient or stable warfarin therapy and thus an increase in FVII would be expected to reduce the INR.…”

Section: Recombinant Factor Viia and Oac Treatmentmentioning

confidence: 99%

Recombinant FVIIa in the Treatment of Warfarin Bleeding

Berntorp¹

2000

Semin Thromb Hemost

View full text Add to dashboard Cite

Patients receiving oral anticoagulant treatment have abnormally low levels of functional vitamin K-dependent coagulation proteins and consequently a clear risk of hemorrhagic complications. The incidence of hemorrhages has been reported to be around 0.6-0.7% per month at a therapeutic International Normalized Ratio (INR) and the incidence of major hemorrhagic events is substantial. Therefore, the ability to reverse the anti-vitamin K effect is of utmost importance, and if an immediate reversal is necessary, plasma or prothrombin complex concentrates are used. As plasma-derived products carry the risk of transmission of blood-borne viruses and also of thromboembolic complications, it is desirable to test new potential tools for oral anticoagulant reversal. Recombinant factor VIIa (FVIIa) has been tested in rats and humans treated with antivitamin K drugs with seemingly good effect on hemostasis and laboratory parameters. Even if more data are needed before any definite conclusions can be drawn, the outlook so far seems promising.

show abstract

Half-Life Time and Control Frequency of Vitamin K-Dependent Coagulation Factors

Cited by 8 publications

References 6 publications

Which Coagulation Factors Interfere with the One-Stage Prothrombin Time?

Which Coagulation Factors Interfere with the One-Stage Prothrombin Time?

Coagulation Factor VII and Plasma Triglycerides

Recombinant FVIIa in the Treatment of Warfarin Bleeding

Contact Info

Product

Resources

About